Evelo Biosciences
- Company typePublic
- Founded2015
- HeadquartersCambridge, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Evelo Biosciences firmographics
Firmographics- Name
- Evelo Biosciences
- Legal name
- Evelo Biosciences, Inc.
- Website
- https://evelobio.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Evelo Biosciences industry classification
Industry- Product category
- Immunomodulatory Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Evelo Biosciences is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Evelo Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Pharmaceutical development and commercialization: Pre-revenue clinical-stage biotech company. Revenue expected upon regulatory approval and commercialization of therapeutic candidates EDP1815 and EDP2939 for inflammatory diseases.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Evelo Biosciences product offering
Product offeringCore offering
Evelo Biosciences is a clinical-stage biotechnology company that develops oral biologic therapeutics derived from gut commensal bacteria to modulate immune responses through the small intestinal axis. Its lead candidates, EDP1815 and EDP2939, are designed to treat inflammatory diseases, with Phase 2a clinical trials in psoriasis underway.
Product overview
Evelo Biosciences is a clinical-stage biotechnology company developing immunomodulatory therapies targeting gut-immune interactions for the treatment of various diseases. The company is advancing two lead drug candidates, EDP1815 and EDP2939, both focused on inflammatory disease treatments. Evelo Biosciences is currently conducting Phase 2a clinical trials for psoriasis using its lead therapeutic candidates.
Differentiator
Problem solved
Functional benefit
Products and services
- EDP1815
Quantifiable outcome
- Phase 2a clinical trial in psoriasis underway
Companies that use Evelo Biosciences
Customer profileSegments1 record
Ideal customer profiles2 records
Evelo Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Evelo Biosciences partnerships and signals
Strategic signalScale indicators2 records
Recent moves5 records
Evelo Biosciences competitors and assessment
Company assessmentBroad incumbents
- Amgen: Major biopharmaceutical company with an established immunology and inflammation portfolio including Otezla and Enbrel. Operates broadly in the same inflammatory disease space as Evelo's lead candidates.
- Eli Lilly: Global biopharmaceutical company with growing immunology presence (e.g., Taltz, Olumiant) and active in inflammatory disease R&D. Comparable large-pharma incumbent competing in Evelo's target indications.
- AbbVie: Global biopharmaceutical leader with a dominant immunology franchise including Skyrizi, Risankizumab, and Humira for psoriasis and inflammatory diseases. Represents the established standard of care that Evelo's oral gut-immune approach must differentiate against.
- Bristol-Myers Squibb: Major immunology player with approved biologics for psoriasis and inflammatory diseases (e.g., Sotyktu, Zeposia). Competes in Evelo's target inflammatory disease space and is a likely partner or acquirer of differentiated novel mechanisms.
- Johnson & Johnson: Diversified biopharmaceutical company with a major immunology franchise including Tremfya and Stelara for psoriasis and IBD. Comparable large-pharma presence in Evelo's target indications and a potential strategic partner for novel oral mechanisms.
Direct peers
- Seres Therapeutics: Pioneer in microbiome-based therapeutics with lead programs in inflammatory disease and recurrent C. difficile. Comparable to Evelo as a clinical-stage developer of microbial consortia designed to modulate gut-immune pathways for systemic therapeutic effect.
- Vedanta Biosciences: Clinical-stage biotech developing defined bacterial consortia that modulate the gut-immune axis to treat inflammatory and autoimmune diseases. Closely comparable to Evelo's commensal bacteria-derived oral biologic platform and target indications.
- 4D Pharma: UK-based clinical-stage biotech developing live biotherapeutic products for cancer and gastrointestinal disease. Directly comparable to Evelo's oral microbial therapeutic modality and gut-immune targeting approach.
Emerging players
- Finch Therapeutics: Clinical-stage developer of oral microbial therapies, including programs in inflammatory bowel disease and recurrent C. difficile. Comparable microbial modality and inflammatory disease pipeline overlap with Evelo.
- Second Genome: Clinical-stage biotech using microbiome science to develop therapeutics for inflammatory bowel disease and other inflammatory conditions. Shares Evelo's gut-microbiome-derived therapeutic strategy and inflammatory disease focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Evelo Biosciences social profiles
Digital presenceEvelo Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Evelo Biosciences leadership team
Management profileNumber of profiles
Profiles9 records
Evelo Biosciences funding detail
Funding detailFunding overview
Funding rounds8 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Evelo Biosciences M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Evelo Biosciences
What does Evelo Biosciences do?
Evelo Biosciences is a clinical-stage biotechnology company that develops oral biologic therapeutics derived from gut commensal bacteria to modulate immune responses through the small intestinal axis. Its lead candidates, EDP1815 and EDP2939, are designed to treat inflammatory diseases, with Phase 2a clinical trials in psoriasis underway.
Is Evelo Biosciences a public or private company?
Evelo Biosciences is a public company. It is classified as public and is currently operating.
When was Evelo Biosciences founded?
Evelo Biosciences was founded in 2015. It employs 51 to 100 people.
Where is Evelo Biosciences based?
Evelo Biosciences is headquartered in Cambridge, United States, in the North America region.
How does Evelo Biosciences make money?
One revenue line is on record: pharmaceutical development and commercialization.
Who are Evelo Biosciences's main competitors?
Broad incumbents on record are Amgen, Eli Lilly, AbbVie, Bristol-Myers Squibb and Johnson & Johnson. Direct peers are Seres Therapeutics, Vedanta Biosciences and 4D Pharma. Emerging players are Finch Therapeutics and Second Genome.
Does Evelo Biosciences have an API?
No public API is recorded for Evelo Biosciences.
What industry is Evelo Biosciences in?
Evelo Biosciences's product category is Immunomodulatory Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 325414 and its SIC code is 2834.